Lung Disease News and Research

RSS

New classification criteria for systemic sclerosis published in ACR journal

New classification criteria for systemic sclerosis have just been published and are more sensitive than the 1980 criteria, enabling earlier identification and treatment of this disabling autoimmune disease.

3 Oct 2013

NIH award strengthens pioneering work in cystic fibrosis at Dartmouth's School of Medicine

The National Institutes of Health (NIH) has awarded a $5.9 million grant to support an Institutional Development Award (IDeA) Lung Biology Center of Biomedical Research Excellence (COBRE) at the Geisel School of Medicine at Dartmouth.

1 Oct 2013

Vitamin D levels linked to emphysema

Researchers have found a relationship between emphysema and serum vitamin D levels, suggesting that the vitamin may play a role in modulating lung structure.

30 Sep 2013

Reduced physical activity in COPD not just disease related

Researchers from the Netherlands have shown that physical activity in patients with chronic obstructive pulmonary disease is influenced by both physical and psychosocial factors.

25 Sep 2013

Mild COPD phenotype discovery offers treatment hope

Research indicates that smokers with and without mild chronic obstructive pulmonary disease can be classified into distinct phenotypes on the basis of computed tomography findings.

23 Sep 2013

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.

23 Sep 2013

Mother who smoke during her pregnancy may transmit asthma to future generation

Asthma is a serious public health problem. An estimated 300 million people worldwide suffer from this sometimes deadly lung disease, a number expected to increase to 400 million by 2025. One well-established risk factor for asthma is having a mother who smoked during her pregnancy.

21 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Vera and Paul Guerin Family Congenital Heart Program to be established in Cedars-Sinai Heart Institute

In an effort to lengthen the life span and improve the quality of life for those born with heart defects, longtime Cedars-Sinai supporters Vera and Paul Guerin have donated $10 million to establish the Vera and Paul Guerin Family Congenital Heart Program in the Cedars-Sinai Heart Institute.

20 Sep 2013

Now is the best time to get immunized against influenza, says UAB expert

It is that time of year again to consider the protection offered by a flu shot. One University of Alabama at Birmingham internal medicine expert says with a vaccine already available, it is best to get immunized against influenza now.

20 Sep 2013

IPF World Week underlines the need for integrated approach towards idiopathic pulmonary fibrosis

This year's IPF World Week (September 21-29) sees healthcare professionals, patient advocacy groups, people living with idiopathic pulmonary fibrosis (IPF), who have an estimated median survival time of two to five years, and their families calling for an integrated approach to further strengthen the national and international network of people working to support patients with this fatal orphan lung disease.

20 Sep 2013

GERD prevalence raised even in mild–moderate COPD, bronchiectasis

Researchers from Australia have found that the rate of gastroesophageal reflux disease is twice as high in patients with chronic obstructive pulmonary disease or bronchiectasis as in people without lung disease.

18 Sep 2013

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

Dual-pronged approach to diabetes and COPD needed

Researchers from the USA have found that patients with diabetes and a history of smoking have significantly impaired lung function, even in the absence of overt chronic obstructive pulmonary disease.

17 Sep 2013

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine’s efficacy in treating asthma patients and is not currently approved for this indication.

11 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013

Drug can be delivered safely to people with COPD in both "mist" and "dry powder" inhalers, say experts

An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease (COPD) in both "mist" and traditional "dry powder" inhalers.

10 Sep 2013

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.

9 Sep 2013

Indicators of poor preoperative health predict risk of major medical complications

For older adults undergoing surgery for spinal stenosis, some simple indicators of poor preoperative health predict a high risk of major medical complications, reports a study in the September 1 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

4 Sep 2013

Lung Disease News and Research

New classification criteria for systemic sclerosis published in ACR journal

NIH award strengthens pioneering work in cystic fibrosis at Dartmouth's School of Medicine

Vitamin D levels linked to emphysema

Reduced physical activity in COPD not just disease related

Mild COPD phenotype discovery offers treatment hope

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Mother who smoke during her pregnancy may transmit asthma to future generation

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Vera and Paul Guerin Family Congenital Heart Program to be established in Cedars-Sinai Heart Institute

Now is the best time to get immunized against influenza, says UAB expert

IPF World Week underlines the need for integrated approach towards idiopathic pulmonary fibrosis

GERD prevalence raised even in mild–moderate COPD, bronchiectasis

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Dual-pronged approach to diabetes and COPD needed

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Patients with COPD show improvements in lung function with olodaterol

Drug can be delivered safely to people with COPD in both "mist" and "dry powder" inhalers, say experts

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Indicators of poor preoperative health predict risk of major medical complications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News